JERUSALEM, March 24, 2020 /PRNewswire/ -- BiondVax
Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal
influenza vaccine candidate M-001, announced that all proposed
resolutions were approved at the Company's Annual General Meeting
held today, including the election of three new directors to the
Company's Board of Directors, namely, Dr. Yael Margolin, Mr. Adi
Raviv, and Mr. Samuel Moed.
Mr. Samuel Moed currently serves as Senior Vice
President, Corporate Strategy at Bristol Myers Squibb (BMS; NYSE:
BMY), a global biopharma company focused on innovative
therapeutics, where for the past six years he has led the strategic
direction of the company with close linkage to all of its major
businesses, functions and geographies. Previously, Mr. Moed oversaw
strategy for BMS's Worldwide Pharmaceuticals Group, encompassing a
range of global strategic initiatives, and managed a global
portfolio of strategic alliances. He also led a number of
businesses including as President of U.S. Pharmaceuticals and as
President of Worldwide Consumer Healthcare. Mr. Moed received a BA
in history from Columbia University in
New York City.
Dr. Yael Margolin has
more than 35 years of experience as senior manager, CEO and board
member in venture capital and in the pharmaceutical and biotech
industries, leading strategic and business planning, financing,
team building, product development and corporate partnerships. From
2005 to 2019, Dr. Margolin served as President, Chief Executive
Officer and director of Gamida Cell Ltd. (Nasdaq: GMDA), a clinical
stage biopharmaceutical company, leading the company from
preclinical development through phase 3 international registration
studies. Prior to that, Dr. Margolin was Vice President of Denali
Ventures LLC, a venture capital firm focused on healthcare, and a
program manager at Teva Pharmaceuticals. Dr. Margolin holds a BSc
in biology and a MSc Cum Laude from the department of microbiology,
both from Tel Aviv University in
Israel, a Ph.D. from the
department of membrane research at the Weitzman Institute of
Science in Rehovot, Israel and was
a post-doctoral associate at the Yale
University School of Medicine.
Mr. Adi Raviv is a
senior financial executive with a career spanning over 30 years.
Since April 2016, Mr. Raviv has been
a Principal at Capacity Funding LLC, a company providing working
capital solutions to small businesses. Prior to that, Mr. Raviv
served in a chief financial officer position in two other companies
that provide similar types of funding alternatives – New Era
Lending from May 2015 to March 2016, and Kapitus (formerly, Strategic
Funding Source) from 2009 to 2014. Mr. Raviv has extensive capital
markets, cash management, corporate finance, investor relations,
restructuring, tax and treasury, and transactional experience along
with knowledge of the private equity and venture capital arenas.
Mr. Raviv co-founded THCG, Inc., a publicly traded technology
merchant banking and consulting company (where he was also CFO),
and has been involved with companies in challenging startup,
growth, and turnaround environments. Mr. Raviv has served on the
boards of directors of many private and several public companies,
as well as various non-profit entities. He received a bachelor's
degree in International Relations with honors from the Hebrew University of Jerusalem and an MBA, with
honors, from Columbia University in
New York City.
Concurrently, Ms. Michal Marom
Brikman has resigned her position from the Board of
Directors.
Mr. Mark Germain, Chairman
of the Board of Directors, commented, "On behalf of BiondVax's
Board of Directors, I am pleased to welcome Sam, Yael, and Adi.
Together they bring a wealth of pharma industry leadership and
capital markets experience, traits that should prove valuable as
the Company proceeds towards results from the ongoing pivotal Phase
3 trial."
Continuing, Mr. Germain noted, "Michal has been a valued
member of BiondVax's Board of Directors, and we thank her for her
contributions including as chairperson of the audit committee. We
wish her well in her future endeavors."
Dr. Ron Babecoff, BiondVax's President and CEO, noted,
"BiondVax has significantly progressed from its days as a
startup, and I believe the experience and skill sets of the new
Board members is what the Company needs going forward. We wish all
our stakeholders and friends around the world good health as we
strive to advance the ongoing pivotal, clinical efficacy, Phase 3
trial of the M-001 universal influenza vaccine candidate. At the
same time, I would like to personally thank Michal Marom Brikman for her many years of
significant contributions to BiondVax."
About BiondVax
BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage
biopharmaceutical company developing a universal flu vaccine. The
vaccine candidate, called M-001, is designed to provide
multi-strain and multi-season protection against current and
future, seasonal and pandemic influenza. BiondVax's proprietary
technology utilizes a unique combination of conserved and common
influenza virus peptides intended to stimulate both arms of the
immune system for a cross-protecting and long-lasting effect. In a
total of 7 completed Phase 1/2 and Phase 2 clinical trials
enrolling 818 participants, the vaccine has been shown to be safe,
well-tolerated, and immunogenic. The ongoing pivotal Phase 3
clinical trial aims to assess safety and effectiveness of M-001 in
reducing flu illness and severity. For more information, please
visit www.biondvax.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements reflect the management's current views with respect to
certain current and future events and are subject to various risks,
uncertainties and assumptions that could cause the results to
differ materially from those expected by the management of BiondVax
Pharmaceuticals Ltd. Risks and uncertainties include, but are not
limited to, risks relating to the COVID-19 (coronavirus) pandemic,
the prosecution, timing and results of the ongoing Phase 2 and
Phase 3 trials and any subsequent trials; timing of receipt of
regulatory approval of our manufacturing facility in Jerusalem; ability to demonstrate the efficacy
and safety of the vaccine; the timing of clinical trials and
marketing approvals; the risk that drug development involves a
lengthy and expensive process with uncertain outcome; the ability
of the Company to maintain, preserve and defend its intellectual
property and patents granted; whether our vaccine candidate
will successfully advance through the clinical trial process on a
timely basis, or at all, and receive approval from the U.S. Food
and Drug Administration or equivalent foreign regulatory agencies;
the adequacy of available cash resources and the ability to raise
additional capital when needed. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in our Annual Report on Form 20-F for
the year ended December 31, 2018
filed with the U.S. Securities and Exchange Commission, or SEC,
which is available on the SEC's website, www.sec.gov. We undertake
no obligation to revise or update any forward-looking statement for
any reason.
Contact Details
Joshua E. Phillipson |
+972 8 930 2529 |
j.phillipson@biondvax.com
View original
content:http://www.prnewswire.com/news-releases/new-directors-elected-to-biondvaxs-board-of-directors-301029123.html
SOURCE BiondVax Pharmaceuticals Ltd.